This Market Spotlight report covers the Basal Cell Carcinoma market, comprising key marketed and pipeline drugs, epidemiology, clinical trials, upcoming events, and probability of success, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

• The approved drugs in the basal cell carcinoma space target the immune system, thymidylate synthase, reactive oxygen species/free radicals, programmed death-1 receptor, programmed death ligands (PD-L1 and PD-L2), and Hedgehog signaling pathway. These therapies are administered via the topical, oral, and intravenous routes.
• The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II. Therapies in the pipeline for basal cell carcinoma focus on a wide variety of targets. These drugs are administered via the topical, oral, intravenous, and intradermal routes.
• High-impact upcoming events for drugs in the basal cell carcinoma space comprise topline Phase III trial results for Ameluz and Patidegib Gel, and topline Phase I/II trial results as well as topline Phase II trial results for MW005.
• The overall likelihood of approval of a Phase I solid tumors asset is 5.4%, and the average probability a drug advances from Phase III is 42.1%. Drugs, on average, take 9.8 years from Phase I to approval, compared to 9.7 years in the overall oncology space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for basal cell carcinoma have been in the early and mid-phases of development, with 89% of trials in Phase I–II, and only 11% in Phase III–IV.
• The US has a substantial lead in the number of basal cell carcinoma clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.
• Clinical trial activity in the basal cell carcinoma space is dominated by completed trials. Roche has the highest number of completed clinical trials for basal cell carcinoma, with 18 trials.
• Roche leads industry sponsors with the highest overall number of clinical trials for basal cell carcinoma, followed by Novartis